Clinical Trial Update: Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating aripiprazole for acutely relapsed schizophrenia (and schizoaffective disorder) has completed enrollment/status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• ARIPIPRAZOLE (Aripiprazole)

Snippet

Sponsor: Taiwan Otsuka Pharm. Co., Ltd | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 3 | Status: COMPLETED